SGLT2 Inhibitors and Continuation of Renin Angiotensin Blockade

Dr. Briggs and Brendon Neuen discuss his paper in the December issue of JASN. This article on the CREDENCE and EMPA-CKD clinical trials shows that SGLT2 inhibitors allow more consistent use of RAS blockade in patients with declining renal function.

21 Minuten

7.4 MB

Podcast

Podcaster

Journal of the American Society of Nephrology (JASN)

Wissenschaft , Gesundheit & Fitness

Beschreibung

vor 2 Jahren

Dr. Briggs and Brendon Neuen discuss his paper in the December
issue of JASN. This article on the CREDENCE and EMPA-CKD clinical
trials shows that SGLT2 inhibitors allow more consistent use of RAS
blockade in patients with declining renal function.